Padcev market seen topping $3 billion by 2030

The Business Research Company says the global Padcev market is entering a high-growth phase, with sales projected to pass $3 billion by 2030. North America and the U.S. are expected to lead, while urothelial cancer remains the biggest use case and the main driver of demand.

Why it matters: - The Padcev market is projected to become a multibillion-dollar oncology niche by 2030. - Growth in Padcev use points to rising demand for targeted therapies in urothelial and bladder cancers. - The forecast also highlights how antibody-drug conjugates are gaining traction in cancer treatment.

What happened: - The Business Research Company released its "Padcev Market Report 2026 – Market Size, Trends, And Global Forecast 2026-2035." - The report projects the global Padcev market will surpass $3 billion in 2030. - The report says the market will grow at a 21% compound annual growth rate through 2030. - North America is expected to be the largest region in 2030, at $1.4 billion. - The U.S. is expected to be the largest country in 2030, at $1.3 billion. - The report says urothelial cancer will be the largest indication segment, accounting for 87% of the market, or about $3 billion, in 2030.

The details: - Padcev is measured against a 2030 oncology drugs parent market of about $441 billion. - The broader pharmaceuticals industry is projected at $2,496 billion by 2030. - Padcev would represent about 1% of the oncology drugs market and nearly 0.1% of the broader pharmaceuticals market. - North America is forecast to grow from $0.7 billion in 2025 to $1.4 billion in 2030, a 16% CAGR. - The U.S. market is forecast to grow from $0.6 billion in 2025 to $1.3 billion in 2030, a 15% CAGR. - The report links North American growth to advanced urothelial carcinoma prevalence, broader use of antibody-drug conjugates, reimbursement support, oncology investment, and physician preference for targeted treatments. - The report links U.S. growth to advanced oncology centers, precision medicine use, awareness of urothelial therapies, oncology specialist availability, and adoption of targeted products in treatment pathways. - The Padcev market is segmented by clinical indication into urothelial cancer and bladder cancer. - The Padcev market is segmented by distribution channel into retail pharmacies and online pharmacies. - The Padcev market is segmented by end-user into hospitals, clinics, ambulatory care, and home care. - The report says urothelial cancer will be supported by rising incidence, demand for advanced-stage therapies, clinical evidence for antibody-drug conjugate efficacy, treatment-guideline adoption, and biomarker-driven treatment strategies. - The report says the urothelial cancer segment is projected to grow by $2 billion from 2025 to 2030. - The bladder cancer segment is projected to grow by $0.3 billion over the same period. - Together, the urothelial cancer and bladder cancer segments are projected to add more than $2.3 billion in market value by 2030. - The report says rising global incidence of urothelial and bladder cancer is expected to contribute about 1.5% annual growth. - The report says increasing adoption of antibody-drug conjugates is expected to contribute about 1.0% annual growth. - The report says expanding regulatory approvals and combination therapy use is expected to contribute about 0.8% annual growth. - The report adds new 2026 features including market attractiveness scoring, TAM analysis, company scoring matrix graphics and tables, Excel-based forecasting dashboards, market hotspots infographics, key technologies and future trend analysis, plus updated graphics and tables. - The report also says the company has published more than 30,000 reports across 27 industries and 60 geographies, backed by 1,500,000 datasets, secondary research and interviews with industry leaders. - The company's website is available at More information.

Between the lines: - The forecast suggests Padcev is benefiting from a broader shift toward precision oncology and targeted delivery platforms. - The concentration of value in urothelial cancer indicates that growth is still tightly tied to one core indication. - The report's strong regional outlook for North America and the U.S. implies reimbursement and clinical infrastructure remain central to uptake. - The growth drivers are cumulative rather than singular, with disease burden, regulation and combination regimens all reinforcing demand.

What's next: - The market's next phase will likely depend on whether broader approvals and combination strategies translate into wider use. - The report points to continued momentum in specialized cancer care settings as targeted therapies move deeper into standard treatment pathways. - Investors and competitors will likely watch whether bladder cancer closes the gap with urothelial cancer as the market expands.